Immunotherapeutic interventions are showing effectiveness across a wide range of cancer types, but only a subset of patients shows clinical response to therapy. Responsiveness to checkpoint blockade immunotherapy is favoured by the presence of a local, CD8⁺ T cell-based immune response within the tumour microenvironment. As molecular analyses of tumours containing or lacking a productive CD8⁺ T cell infiltrate are being pursued, increasing evidence is indicating that activation of oncogenic pathways in tumour cells can impair induction or execution of a local antitumour immune response. This Review summarizes our current knowledge of the influence of oncogenic effects on evasion of antitumour immunity.

免疫治疗干预措施在多种癌症类型中显示出有效性，但只有一小部分患者对治疗表现出临床反应。肿瘤微环境中存在基于 CD8 ⁺ T 细胞的局部免疫反应，有利于检查点阻断免疫疗法的反应。随着对含有或缺乏高效 CD8 ⁺ T 细胞浸润的肿瘤进行分子分析，越来越多的证据表明肿瘤细胞中致癌途径的激活可能会损害局部抗肿瘤免疫反应的诱导或执行。这篇综述总结了我们目前关于致癌效应对逃避抗肿瘤免疫的影响的知识。